This article was originally published in The Rose Sheet
Executive SummaryFederal agencies' responses to recommendations on non-animal test methods for assessing allergic contact dermatitis hazard potential of chemicals is now available, reports the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods. Two test methods recommended to the agencies by ICCVAM were the murine local lymph node assay (LLNA), which uses 20% fewer animals than the original protocol recommended in 1999, and the reduced murine local lymph node assay (rLLNA), which can reduce animal use by 40% compared with the standard LLNA. ICCVAM gave agencies - including FDA, the EPA and the Consumer Product Safety Commission - 180 days to respond to its favorable recommendation for the tests, which comes after consideration of a peer review panel report, public comments and feedback from its Scientific Advisory Committee on Alternative Toxicological Methods (1"The Rose Sheet" Oct. 19, 2009, In Brief)
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.